Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Morgan Stanley

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart Presents at Morgan Stanley 18th Annual Global Healthcare Conference Transcript

Intuitive Surgical, a fast growing medical devices company with a market capitalization of $84 billion, has seen its stock rise by 20% this year, outperforming the broader indices, with the S&P 500 up 4%. The stock now trades at over 72x projected 2020 earnings, despite the fact that the company.

Intuitive Surgical Stock Headed To $1,000 Levels?

Intuitive Surgical: Current Valuation Is Hard To Justify

Mastercard

Palo Alto Networks

Amazon

Over time, these high-growth companies should deliver big-time gains for investors.

Got $3,000? 4 Surefire Growth Stocks to Buy Now

Two analysts in two weeks voice grudging approval of the robotic surgery stock.

Why Intuitive Surgical Stock Popped Today

Intuitive Surgical: Time For A Pullback

NextEra Energy

These great companies have handsomely rewarded long-term shareholders.

3 Unstoppable Stocks to Invest $2,000 In Right Now

Edwards Lifesciences

Boston Scientific

Guardant Health Inc

Novocure

Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.

Intuitive Surgical, Edwards Lifesciences Lead Five Top Stocks To Watch As Coronavirus Cases Fall, Elective Procedures Rise

Adobe

AutoZone

Blackrock Inc

Alphabet

Sherwin-Williams

Apple and Tesla both recently announced stock splits. This could just be the beginning for high-quality, high-dollar companies.

7 Companies That Should Split Their Stocks

ISRG stock is on the rise this year, but Intuitive Surgical stock performance is lagging its peers in its medical technology group. So, is it time to take on this robotic surgery stock?

Intuitive Surgical Is Adding Onto A Recent Breakout — Is ISRG Stock A Buy?

Intuitive Surgical's market is expected to grow to $11.8 billion by 2025 at a CAGR of 12.1%.

Intuitive Surgical Is A Fundamentally Strong Company With A Competitive Advantage Operating In A Growing Market

It's probably a question of when and not if.

3 Reasons Why Intuitive Surgical Could Be Headed for a Stock Split

Intuitive Surgical (ISRG) continues to benefit from rising da Vinci Surgical System, strong international presence and robust recurring revenue base.

Here's Why You Should Hold on to Intuitive Surgical Stock Now

Atlantica Sustainable Infrastructure

Brookfield Property Partners

Electronic Arts

Diamondback Energy

Freshpet

Lululemon Athletica

Middleby

SVB Financial Group

WD-40

When investors think of Nasdaq stocks to buy, they mostly gravitate to technology names. Here are 10 stocks that don't follow this trend.

10 Nasdaq Stocks to Buy and Hold for the Long Haul

The robotic-surgery leader is benefitting as its rivals falter.

Why Intuitive Surgical Stock Surged 20% in July

Intuitive Surgical’s stock lost more than 38% – dropping from $600 at the beginning of the year to below $370 in late March – then spiked 85% to around $680 now. That means it is well above the levels where it started the year.

Despite An 85% Rally Intuitive Surgical Stock Can Grow Further

Intuitive Surgical, Inc.'s (NASDAQ: ISRG) second-quarter report Tuesday was “surprisingly positive,” according to Canaccord Genuity.

Intuitive Surgical's Outlook 'Has Never Been Stronger,' Analyst Says After Q2 Report

Revenues and profits still fell significantly, however -- which was expected due to the coronavirus pandemic.

Intuitive Surgical Trounces Analysts' Q2 Estimates

DaVita

Medtronic

Owens & Minor

1Life Healthcare

Tandem Diabetes Care

Walgreens

With so much focus and attention geared toward the novel coronavirus and the COVID-19 pandemic, health care has been affected in many strange ways.

7 Post-Coronavirus Health Care Stocks That Will Win in the Years Ahead

Intuitive Surgical's (ISRG) second-quarter results reflect weak performance across all businesses and lower revenues.

Intuitive Surgical (ISRG) Q2 Earnings Top Estimates, Down Y/Y

Intuitive Surgical, Inc. (ISRG) CEO Gary Guthart on Q2 2020 Results - Earnings Call Transcript

Shares of Intuitive Surgical (NASDAQ:ISRG) increased 4.12%% in after-market trading after the company reported Q2 results.

Recap: Intuitive Surgical Q2 Earnings

Late Tuesday, Intuitive Surgical reported adjusted earnings of $1.11 per share on $852 million in sales for its second quarter ended June 30. In response, ISRG stock popped.

Robotic Surgery Leader Extends Breakout After Crushing Quarterly Estimates

Intuitive Surgical: Its Competitive Advantage Extended

With cases surging again, this company could be deeply affected.

News for Intuitive Surgical Stock (ISRG)